MedTrace Logo

PET/CT Characterization of Treatment Resistance

NCT05647564 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-02-17

No results posted yet for this study

Summary

This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are either scheduled to start a second-generation androgen receptor (AR) targeted therapy (such as enzalutamide, abiraterone, or apalutamide) or are already being treated with one. Participants can expect to be in the study for at least 9 months, and up to 2 years.

Conditions

Interventions

DIAGNOSTIC_TEST

F-fluorodeoxyglucose positron emission tomography (FDG PET)

Imaging scan

DIAGNOSTIC_TEST

prostate-specific membrane antigen positron emission tomography (PSMA PET)

Imaging scan

Sponsors & Collaborators

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Glenn Liu, MD · University of Wisconsin, Madison

  • Robert Jeraj, PhD · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-06
Primary Completion
2026-09-01
Completion
2026-09-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647564 on ClinicalTrials.gov